Sciences announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81%, ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...

Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three ...

Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...

New insights and emerging scientific trends incorporated into our ACLF development plan, with data readout from 4 clinical trials anticipated by the end of 2025, including data from 3 new clinical ...

Many bacterial-linked illnesses, such as inflammatory bowel disease or colorectal cancer, are associated with an overgrowth of gut bacteria thought to be bad actors. But when researchers used a ...

Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...

T here's no part of the morning routine as sacred to so many of us as that first sip of freshly brewed coffee. In fact, most ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.